Table 2 2D/3D dose normalisation and alternative metrics: Dose between 2D and 3D in vitro test systems was standardised in terms of total nanoparticle mass to total cell number at time of dosing (Table Left) (see Methods). For each exposure route used here, alternative dose-metrics (as applicable) are also presented (Table Right) to facilitate comparison. In-medium exposures (2D/3D In-Medium) are provided in total mass (μg), mass/volume (μg/mL) and number/volume (nM) units. Topical, acetone-deposited exposures (3D Topical) are presented in total mass (μg) and mass/surface area (μg/cm2) units
From: Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDermâ„¢)
This study’s 2D/3D equivalent* exposures: | Alternative dose metrics for each exposure route: (as applicable) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
2D In-Medium (μg/mL) | 3D In-Medium (μg) | 3D Topical (μg) | 2D In-Medium (μg) | 3D In-Medium (μg/mL) | 3D Topical (μg/cm2) | 3D In-Medium (nM) | 2D In-Medium (nM) | ||
| Â | Â | Â | Â | Â | Â | 16Â nm-SiO2 | 85Â nm-SiO2 | 16Â nm-SiO2 | 85Â nm-SiO2 |
0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.00 | 0.0 | 0.00 |
100 | 150 | 150 | 1000.0 | 167.8 | 235.9 | 49.0 | 0.33 | 29.2 | 0.19 |
200 | 300 | 300 | 2000.0 | 336.7 | 473.4 | 98.4 | 0.66 | 58.4 | 0.39 |
300 | 450 | 450 | 3000.0 | 505.6 | 710.9 | 147.7 | 0.99 | 87.7 | 0.58 |
− | 1000 | 1000 | − | 1111.1 | 1562.5 | 324.6 | 2.17 | − | − |